As regards, Rosich et al reported that the activity of EVE is limited by AKT re-phosphorylation and suggested that targeting the PI3K/AKT/mTOR pathway at multiple levels is likely to be a more effective strategy for the treatment of mantle cell lymphoma [32]. This evidence concerns the gene AKT1 and mantle cell lymphoma.